Genprex’s Reqorsa demonstrates anti-tumor effects in NSMLC

Genprex’s (GNPX) research collaborators presented positive preclinical data for Reqorsa Gene Therapy for the treatment of KRASG12C mutant non-small cell lung cancer, or NSCLC. This data were presented at the 2025 American Association for Cancer Research Annual Meeting in Chicago. In the poster, researchers demonstrated that Reqorsa effectively overcomes sotorasib, or Lumakras, -acquired resistance in KRASG12C mutant NSCLC mouse xenografts. The H23AR tumors exhibited significantly lower sensitivity to sotorasib than their parental counterparts. However, treatment with Reqorsa was highly effective in controlling tumor growth compared to treatment with sotorasib alone or the control groups. In conclusion, researchers demonstrated that Reqorsa, alone or in combination with sotorasib, induced apoptosis, inhibited colony formation, and showed significant antitumor efficacy in KRASG12C mutant sotorasib-acquired resistant xenograft and PDX tumors.